• Cyclodextrin-Induced Cholesterol Depletion Inhibits TRPV1 No

  2026-07-07

  This study demonstrates that β-cyclodextrin derivatives suppress TRPV1- and TRPA1-mediated nociceptive behaviors in mice by depleting membrane cholesterol, offering a non-antagonist approach to peripheral analgesia. These findings reveal the functional importance of lipid rafts in TRP channel activation and suggest new strategies for pain modulation.

• Losartan as a Mechanical Microenvironment Modulator in Tumor

  2026-07-06

  Explore how Losartan, a potent angiotensin II receptor antagonist, enables next-generation research into both cardiovascular physiology and tumor microenvironment remodeling. This article uniquely connects Losartan’s vascular and oncology applications, revealing its value for advanced experimental design.

• Gap19: Selective Connexin 43 Hemichannel Blocker in Immune &

  2026-07-06

  Gap19’s selective inhibition of Cx43 hemichannels enables precise dissection of neuroglial and immune signaling without disrupting gap junctions. Its robust validation in models of cerebral ischemia and inflammation-driven macrophage polarization empowers researchers to push the boundaries of neuroprotection and cardiovascular inflammation studies.

• Hierarchical ROS-Responsive Nanoplatform Repairs Macrophages

  2026-07-05

  This study introduces a hierarchically targeted, ROS-responsive nanoparticle-hydrogel system for treating diabetic periodontitis by repairing mitochondrial dysfunction in M1 macrophages. The platform disrupts the ROS-inflammation feedback loop, leading to reduced tissue damage and enhanced bone regeneration, offering a significant therapeutic advance beyond conventional treatment.

• Cyclodextrin-Induced Cholesterol Depletion Modulates TRPV1/T

  2026-07-04

  This study demonstrates that cyclodextrin derivatives reduce pain and neurogenic inflammation by depleting membrane cholesterol and thereby inhibiting TRPV1 and TRPA1 activation. The findings introduce a mechanistically distinct, non-antagonist approach to peripheral analgesia, with implications for sensory neuron desensitization strategies.

• Resiniferatoxin (RTX): Precision TRPV1 Silencing for Transla

  2026-07-03

  Explore how Resiniferatoxin (RTX) enables chemical inactivation of TRPV1, driving next-generation translational research in neuropathic and osteoarthritis pain. This article blends mechanistic rigor, protocol insight, and strategic vision—anchored by recent breakthroughs and actionable guidance for researchers.

• GPR107 Loss Drives Diabetic Nephropathy via AT1R/Ca2+ Pathwa

  2026-07-03

  Xu et al. reveal that GPR107 deficiency exacerbates diabetic nephropathy by disrupting collagen IV homeostasis in podocytes through impaired AT1R endocytosis and sustained angiotensin II signaling. These findings highlight a novel mechanistic link between endocytic regulation and matrix accumulation, with implications for targeted kidney research and therapeutic exploration.

• HDAC Inhibition in Neuroblastoma: M344 Versus Vorinostat Ins

  2026-07-02

  Brumfield et al. evaluated the HDAC inhibitor M344 in neuroblastoma models, demonstrating enhanced histone acetylation, tumor suppression, and reduced toxicity compared to Vorinostat. These results strengthen the rationale for advanced HDAC inhibition strategies in pediatric oncology and inform future experimental designs.

• Cell Senescence β-Galactosidase Staining Kit: Applied Workfl

  2026-07-02

  Leverage the Cell Senescence β-Galactosidase Staining Kit for artifact-free, selective detection of senescent cells in both research and drug discovery. This guide details optimized protocols, advanced use-cases, and troubleshooting strategies—enabling robust, reproducible results even in challenging experimental settings.

• Baicalin Methyl Ester: Applied Workflows for Intestinal Barr

  2026-07-01

  Baicalin methyl ester, a potent esterified derivative of baicalin, offers targeted modulation of intestinal barrier pathways and robust anti-inflammatory effects. This guide delivers step-by-step workflows, optimization strategies, and practical troubleshooting to maximize reproducibility in LPS-induced intestinal barrier damage research.

• Strategic Use of Losartan in Translational Cardiovascular Re

  2026-07-01

  This thought-leadership article examines the strategic integration of Losartan, a selective angiotensin II type 1 receptor antagonist, in translational cardiovascular research. Framed by the latest evidence on vascular biology and immune modulation, it delivers mechanistic insights, protocol guidance, and a critical outlook on Losartan’s value in advancing the understanding of hypertension and beyond. The discussion uniquely bridges emerging findings in tumor immunology and vascular repair, offering a forward-thinking roadmap for researchers seeking to translate molecular insights into therapeutic innovation.

• NADH (Reduced-form Nicotinamide Adenine Dinucleotide) CAS No

  2026-06-30

  This article presents scenario-driven, evidence-based guidance for biomedical researchers using NADH (Reduced-form Nicotinamide Adenine Dinucleotide) CAS No. 58-68-4 (SKU C8749) in cell viability, proliferation, and mitochondrial assays. Leveraging validated protocol parameters and quantitative data, we demonstrate how SKU C8749 enables reproducible, high-sensitivity workflows, with special attention to mitochondrial electron transport chain research, disease modeling, and photocatalytic cancer therapy.

• Praeruptorin A Attenuates Ferroptosis in Doxorubicin Cardiot

  2026-06-30

  This study identifies Praeruptorin A as a novel inhibitor of ferroptosis, demonstrating its ability to reduce iron overload and protect against doxorubicin-induced cardiomyopathy in mice. The work pioneers high-throughput screening of herbal compounds using Fe2+ probes and elucidates the mechanistic inhibition of DMT1, offering new avenues for cardioprotection during chemotherapy.

• Resiniferatoxin (RTX): Optimizing Analgesic Assays in the La

  2026-06-29

  This article guides biomedical researchers and technicians in the practical selection and application of Resiniferatoxin (RTX, SKU BA7012) for pain, viability, and cytotoxicity assays. We address common workflow challenges and provide scenario-driven insights, highlighting RTX's ultra-potent TRPV1 agonism, validated dosing, and supplier reliability. All recommendations are grounded in peer-reviewed evidence and real-world lab practice.

• GDC-0941: Advanced PI3K Inhibition in Precision Cancer Model

  2026-06-29

  Explore how GDC-0941, a potent PI3K inhibitor, drives innovation in preclinical oncology by enabling nuanced PI3K/Akt pathway inhibition and resistance modeling. Discover practical protocols, advanced applications, and insights from recent research, setting this article apart from conventional overviews.

449 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page